Algae could open up new avenues for developing an effective treatment to prevent limb amputation in people with severely limited blood flow, reports a new study. The findings of the study are published in the journal npj Regenerative Medicine.
A new algae-based treatment could reduce the need for amputation in people with critical limb ischemia (CLI), according to new research funded by the British Heart Foundation.
Better Option than Amputation can Save Your Life and Limbs
Blood flow restoration is the better option than amputation for treating severe peripheral artery disease, otherwise called as critical limb ischemia.
Advertisement
‘New algae-based capsules containing macrophages may increase blood flow in the limbs where tissue has been damaged, thereby offering a new potential treatment to prevent limb amputation.’
Tweet it Now
A team of researchers at St Thomas' Hospital and King's College London have made small capsules from brown algae which hold macrophages, a type of white blood cell. Tests in mice have shown that these algae capsules may be able to increase blood flow in the limbs where tissue has been damaged. The researchers now hope to progress this research into human clinical trials to help the people visiting the hospital with critical limb ischemia (CLI). It is estimated that there are up to 60,000 new cases of CLI per year in the UK.
Scientists have been experimenting with cells as a treatment to grow arteries in the leg for years. However, these treatments have not been effective in humans. A big challenge is that many of the cells injected into the injured area die, move away to surrounding areas, or are detected as 'foreign' by the immune system and rejected.
![Spirulina]( "Spirulina")
Spirulina is a blue-green algae that is grown globally as a health supplement. Of late there is an effort to promote spirulina as the "food of the future".
In this study, surgeon Professor Bijan Modarai and his team of scientists delivered the new algae-based capsules containing macrophages to areas of injured muscle tissue in the back legs of mice. Alginate from the cell walls of brown algae, which is mainly found in cold waters in the Northern Hemisphere, was used to form the capsules. They found that these macrophages successfully remained in the injured area, new blood vessels formed, and as a result, more blood reached the damaged area.
CLI is a serious condition which occurs when the arteries in the limbs become blocked as a result of a build-up of fatty deposits, reducing blood flow to the hands and feet. Smoking, diabetes, obesity and high blood pressure can all lead to CLI. If blood flow is not restored, up to 50 percent of people with CLI will either die or need amputation within one year.
Currently, to treat CLI and restore blood flow in the limbs, the blocked section of the artery has to be either bypassed during surgery or widened using a small piece of expandable mesh called a stent. However, in up to a third of patients, these methods will eventually fail or are not possible, to begin with, and amputation is the only option.
Professor Bijan Modarai, therefore, hopes that this new way of delivering cells could be the key to creating an effective treatment for people suffering from CLI.
Professor Bijan Modarai, Professor of Vascular Surgery and BHF Senior Fellow at King's College London/St Thomas' Hospital, said:
"We hope that this new method of cell therapy will greatly reduce the need for limb amputations in those people whose CLI is untreatable, and would otherwise have no other option.
"The beauty of this new algae-based treatment is that it harnesses the potential of natural materials. Not only does this make it a very attractive solution, but we know we can use it to safely treat people with CLI."
Professor Metin Avkiran, Associate Medical Director at the British Heart Foundation which funded the research, said:
"You might associate algae with your garden pond, but our researchers are proving these diverse organisms could hold the key to a new treatment for one of the leading causes of limb amputation - CLI."
"Losing a limb is an all too devastating reality for many patients with CLI. The condition is caused by blockages in arteries that supply blood to the legs and feet, and is triggered by the same process that blocks coronary arteries when someone has a heart attack."
"This research brings us a step closer to finding treatments for the thousands of people affected by this disabling condition in the UK."
Source: Eurekalert
Spirulina
Spirulina is a blue-green algae that is grown globally as a health supplement. Of late there is an effort to promote spirulina as the "food of the future".
Advertisement
In this study, surgeon Professor Bijan Modarai and his team of scientists delivered the new algae-based capsules containing macrophages to areas of injured muscle tissue in the back legs of mice. Alginate from the cell walls of brown algae, which is mainly found in cold waters in the Northern Hemisphere, was used to form the capsules. They found that these macrophages successfully remained in the injured area, new blood vessels formed, and as a result, more blood reached the damaged area.
CLI is a serious condition which occurs when the arteries in the limbs become blocked as a result of a build-up of fatty deposits, reducing blood flow to the hands and feet. Smoking, diabetes, obesity and high blood pressure can all lead to CLI. If blood flow is not restored, up to 50 percent of people with CLI will either die or need amputation within one year.
Currently, to treat CLI and restore blood flow in the limbs, the blocked section of the artery has to be either bypassed during surgery or widened using a small piece of expandable mesh called a stent. However, in up to a third of patients, these methods will eventually fail or are not possible, to begin with, and amputation is the only option.
Professor Bijan Modarai, therefore, hopes that this new way of delivering cells could be the key to creating an effective treatment for people suffering from CLI.
Professor Bijan Modarai, Professor of Vascular Surgery and BHF Senior Fellow at King's College London/St Thomas' Hospital, said:
"We hope that this new method of cell therapy will greatly reduce the need for limb amputations in those people whose CLI is untreatable, and would otherwise have no other option.
"The beauty of this new algae-based treatment is that it harnesses the potential of natural materials. Not only does this make it a very attractive solution, but we know we can use it to safely treat people with CLI."
Professor Metin Avkiran, Associate Medical Director at the British Heart Foundation which funded the research, said:
"You might associate algae with your garden pond, but our researchers are proving these diverse organisms could hold the key to a new treatment for one of the leading causes of limb amputation - CLI."
"Losing a limb is an all too devastating reality for many patients with CLI. The condition is caused by blockages in arteries that supply blood to the legs and feet, and is triggered by the same process that blocks coronary arteries when someone has a heart attack."
"This research brings us a step closer to finding treatments for the thousands of people affected by this disabling condition in the UK."
Source: Eurekalert
Cellular Counting Mechanism in Algae Linked to Cancer Genetic Pathway
A protein called CDKG1 is analogous to a human protein called CDK4/6 that stimulates cell proliferation and whose activity is frequently misregulated in cancer.
Advertisement
 Artificial LimbsResearch in the field of bio engineering and advanced amputation procedures have given improved models of artificial limbs that very nearly replicate the functions of real, biological limbs. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
R21/Matrix-M, the world's second malaria vaccine is readily deployable, and cost-effective making it prepared for distribution in areas where it is most essential.
The reverse vaccine uses the liver's natural "non-target" signals to prevent autoimmune responses against naturally decaying cells.
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
